CCL launches JARDY (Empagliflozin) and SITAMET XR (Sitagliptin with Metformin extended Release formulation)

LAHORE, FEB. 2019: CCL Pharmaceuticals started its new year with the launch of two blockbuster products JARDY & SITAMET XR recently in a ceremony held in a local hotel in Lahore.

In continuation of CCL’s promise, we extended the legacy of first mover in diabetes management. JARDY (Empgliflozin) is a newer class of oral prescription medication, which is commonly used to control type 2 Diabetes Mellitus. JARDY is a real Cardio-Protective Anti Diabetic and best in class SGLT2 inhibitor; JARDY (Empagliflozin) is being endorsed by 50 major guidelines around the world.

CCL has also launched SITA-Met XR, which is the line extension of SITA-Met range in extended release formulation.It can be used once a day without any unwanted gastrointestinal side effects ensuring better patient compliance.

Related Posts
Leave a Reply

Your email address will not be published.Required fields are marked *